The Tirzepatide-B12 Adduct: An Impurity That Only Exists in Compounded Product
A March 2026 analysis identified a tirzepatide-B12 adduct in mass-compounded tirzepatide formulated with vitamin B12 — a compound not present in the FDA-approved drug. Here is why that matters more than the marketing does.
The short version
- A March 2026 analysis identified a tirzepatide-B12 adduct in mass-compounded tirzepatide formulated with B12 — a molecular species not found in FDA-approved tirzepatide.
- An adduct is a new chemical entity formed when two molecules bind. It is not the original drug plus a vitamin sitting side by side in a vial.
- Nobody has run safety or efficacy studies on this compound, because until recently nobody knew it was there.
- B12 was added to most compounded GLP-1s for regulatory positioning, not because patients needed it.
If you take compounded tirzepatide, there is a good chance vitamin B12 is in the vial. Providers describe it as a support ingredient — something for energy, or to soften side effects. The real reason it is there has more to do with regulatory strategy than with your metabolism. And a finding published in March 2026 suggests that decision had a chemical consequence nobody planned for.
What an adduct is
When two molecules are dissolved together in solution, they do not always stay separate. Under the right conditions they bond, forming a single new molecule called an adduct. It has its own structure, its own stability profile, and its own biological behaviour. It is not tirzepatide anymore, and it is not B12 anymore.
The March 2026 analysis found exactly this in mass-compounded tirzepatide formulated with B12: a tirzepatide-B12 adduct that does not appear in FDA-approved tirzepatide. The approved product does not contain B12, so it has no opportunity to form.
Manufacturers control for known impurities with established limits and validated assays. An adduct that was not known to exist has no specification, no limit, and no routine test looking for it. You cannot control what you are not measuring.
What we do not know
This is the part that deserves plain language rather than alarm. There is no published evidence that this adduct harms patients. There is also no published evidence that it does not. Specifically, there is no public data on:
- Whether the adduct binds GLP-1 or GIP receptors, and with what potency
- What fraction of the labelled tirzepatide dose has converted into it by the time a vial is used up
- Whether it accumulates over the shelf life of a multidose vial
- How it is metabolised or cleared
- Whether it contributes to immunogenicity
An unstudied compound is not automatically a dangerous one. But when your dosing assumption is that the vial contains a known quantity of a known drug, a molecule that silently converts some portion of that drug into something else undermines the assumption you are titrating on.
Why the B12 is in there at all
Once the FDA declared the GLP-1 shortages resolved, straightforward copies of the brand drug lost their legal cover. Adding an ingredient allowed compounders to argue the product was a personalised formulation rather than a copy. IQVIA reported that as of fall 2025, more than 80% of compounded semaglutide and tirzepatide prescriptions contained supplemental ingredients such as B vitamins including B6, B12, and B3, or levocarnitine.
The FDA's position has been consistent: adding extras does not by itself make a product meaningfully different, and a genuine medical need for a specific patient has to be documented. The adduct finding adds a second problem to the first. The additive strategy was not just legally thin — it changed the chemistry.
Providers offering injectable or brand-name product
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Semaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkMarketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkInjectable-only program with flat monthly plan pricing. An oral option is advertised but has not launched.
See Gala pricing Paid partner linkQuestions worth asking your pharmacy
You are entitled to ask, and a legitimate pharmacy will answer:
- Does my formulation contain B12 or any other added ingredient?
- Is there a documented clinical reason it is in my prescription specifically?
- What potency testing is done at release, and does it test the finished formulation rather than the raw tirzepatide?
- Do you test for degradation products or adducts, and can I see a certificate of analysis?
- What is the beyond-use date, and what stability data supports it?
If you are doing well on a compounded product with B12 and switching would cost you access to treatment entirely, this finding is a reason to ask questions and review with your clinician — not a reason to stop medication abruptly. If you have a realistic path to an FDA-approved product, this is one more argument for taking it.
The broader pattern
This finding sits inside a wider quality picture. The FDA has warned that some compounded semaglutide and tirzepatide products carry false label information, including pharmacy names that either do not exist or did not make the drug. As of May 31, 2026, the agency had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, while noting these are likely undercounts because many state-licensed pharmacies are not required to report.
The adduct is not a scandal on its own. It is evidence for a structural point: when a product is not FDA-approved, nobody has systematically characterised what is actually in the vial, and findings like this one surface years after millions of doses have been administered.
Sources
- March 2026 analytical study identifying a tirzepatide-B12 adduct in mass-compounded tirzepatide formulated with vitamin B12.
- IQVIA analysis of supplemental ingredients in compounded GLP-1 prescriptions, fall 2025.
- US Food and Drug Administration warning letters to telehealth companies, February 2026.
- FDA adverse event report totals for compounded semaglutide and tirzepatide as of May 31, 2026.
- FDA guidance on compounded drug products and label accuracy.